Price, M. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017–2021. Neuro. Oncol. 26VI1 – VI85 (2024).
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352987–996 (2005).
Taslimi, S., Ye, V. C., Wen, P. Y. & Zadeh, G. Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma. Neuroncol. Adv. 3vdab029 (2021).
Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 61003–1010 (2020).
Chen, A. T. C. et al. Prospective randomized phase 2 trial of hypofractionated stereotactic radiation therapy of 25 Gy in 5 fractions compared with 35 Gy in 5 fractions in the reirradiation of recurrent glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 1191122–1132 (2024).
Werlenius, K. et al. Effect of disulfiram and copper plus chemotherapy vs chemotherapy alone on survival in patients with recurrent glioblastoma: a randomized clinical trial. JAMA Netw. Open 6e234149 (2023).
Tsien, C. I. et al. NRG Oncology/RTOG1205: a randomized phase ii trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. J. Clin. Oncol. 411285–1295 (2023).
Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20359–371 (2023).
Peng, L., Sferruzza, G., Yang, L., Zhou, L. & Chen, S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell. Mol. Immunol. 211089–1108 (2024).
Choi, B. D. et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N. Engl. J. Med. 3901290–1298 (2024).
Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Night. With. 301320–1329 (2024).
Brown, C. E. et al. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Night. With. 301001–1012 (2024).
Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637708–715 (2025).
Vitanza, N. A. et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Night. With. 31861–868 (2025).
Reilly, E. B. et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol. Cancer Ther. 141141–1151 (2015).
Bartolomé, R. A. et al. IL13 receptor α2 signaling requires a scaffold protein, FAM120A, to activate the FAK and PI3K pathways in colon cancer metastasis. Cancer Res. 752434–2444 (2015).
Lassman, A. B. et al. Comparison of biomarker assays for EGFR: implications for precision medicine in patients with glioblastoma. Clin. Cancer Res. 253259–3265 (2019).
Joshi, B. H., Plautz, G. E. & Puri, R. K. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 601168–1172 (2000).
Yin, Y. et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol. Ther. 302537–2553 (2022).
Schulz, K. F., Altman, D. G., Moher, D. & the, C.G. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 818 (2010).
Logun, M. et al. Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell 32181–190.e184 (2025).
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25625–638 (2019).
Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Night. With. 29803–810 (2023).
Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21501–521 (2024).
Grant, S. J. et al. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant. Cell. Ther. 28294–302 (2022).
Kirouac, D. C., Zmurchok, C. & Morris, D. Making drugs from T cells: the quantitative pharmacology of engineered T cell therapeutics. NPJ Syst. Biol. Appl. 1031 (2024).
Turicek, D. P., Giordani, V. M., Moraly, J., Taylor, N. & Shah, N. N. CAR T-cell detection scoping review: an essential biomarker in critical need of standardization. J. Immunother. Cancer 11E006596 (2023).
Rotte, A. et al. Dose–response correlation for CAR-T cells: a systematic review of clinical studies. J. Immunother. Cancer 10e005678 (2022).
Baur, K. etc. CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas. Bone Marrow Transplant. 581048–1050 (2023).
Ellingson, B. M. et al. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro. Oncol. 251017–1028 (2023).
Rhee, J. Y., Ghannam, J. Y., Choi, B. D. & Gerstner, E. R. Labeling T cells to track immune response to immunotherapy in glioblastoma. Tomography 9274–284 (2023).
Barajas, RF Jr. et al. [18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab. Neuroncol. Pract. 9246–250 (2022).
Ellingson, B. M. et al. Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro. Oncol. 241219–1229 (2022).
Thokala, R. et al. High-affinity chimeric antigen receptor with cross-reactive scFv to clinically relevant EGFR oncogenic isoforms. Front. Oncol. 11664236 (2021).
Yin, Y. et al. Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol. Ther. Oncolytics 1120–38 (2018).
Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro. Oncol. 231231–1251 (2021).
O’Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9ALOHA .99 (2017).
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 3711507–1517 (2014).
